Cargando…
STAT6 siRNA Matrix-Loaded Gelatin Nanocarriers: Formulation, Characterization, and Ex Vivo Proof of Concept Using Adenocarcinoma Cells
The clinical utility of siRNA therapy has been hampered due to poor cell penetration, nonspecific effects, rapid degradation, and short half-life. We herewith proposed the formulation development of STAT6 siRNA (S6S) nanotherapeutic agent by encapsulating them within gelatin nanocarriers (GNC). The...
Autores principales: | Youngren, Susanne R., Tekade, Rakesh K., Gustilo, Brianne, Hoffmann, Peter R., Chougule, Mahavir B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806510/ https://www.ncbi.nlm.nih.gov/pubmed/24191252 http://dx.doi.org/10.1155/2013/858946 |
Ejemplares similares
-
Formulation Development and Evaluation of Hybrid Nanocarrier for Cancer Therapy: Taguchi Orthogonal Array Based Design
por: Tekade, Rakesh K., et al.
Publicado: (2013) -
Poly(amidoamine) Dendrimer Nanocarriers and Their
Aerosol Formulations for siRNA Delivery to the Lung Epithelium
por: Conti, Denise S., et al.
Publicado: (2014) -
Exosomes as nanocarriers for siRNA delivery: paradigms and challenges
por: Shahabipour, Fahimeh, et al.
Publicado: (2016) -
Nanocarriers for delivery of siRNA as gene silencing mediator
por: Morales-Becerril, Aideé, et al.
Publicado: (2022) -
Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non–small-cell Lung Cancer
por: Espana-Serrano, Laura, et al.
Publicado: (2016)